Tests infrared light treatment in adults with Crohn's disease
Tests far infrared light therapy at different strengths against sham in Crohn's disease.
Plain-language title generated from the registry record
Registry title: The Assessment of Infrared Treatment for Crohn's Disease
Key facts
- Where
- Tel Aviv, IsraelSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06146816, who can take part
Where in Israel
- Dep. of Gastroenterology, Tel Aviv Sourasky Medical CenterTel Aviv, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shmuel Kivity, MD
- Trial code
- NCT06146816
- Record updated
- 24 February 2026
- Original description
The goal of this clinical trial is to test the safety and efficacy of far Infra-red (fIR) therapy in Crohn's disease patients.Read full original descriptionShow less
An Exploratory Clinical Trial for the Assessment of Infrared Treatment for Crohn's Disease
The goal of this clinical trial is to test the safety and efficacy of far Infra-red (fIR) therapy in Crohn's disease patients.
The main questions it aims to answer are:
1. Is infrared therapy safe for treating Crohn's disease patients? 2. Is infrared therapy effective for treating Crohn's disease?
Participants will be asked to attend 10 treatments of fIR therapy, provide stool and blood samples and answer questionnaires.
Researchers will compare between 4 treatments: three intensities of fIR therapy and placebo treatment to explore which intensity is most effective for treating Crohn's disease.
Inclusion: An established Crohn's disease; 18 < age < 80; No therapy or on constant medicinal regimen throughout the study period: mesalamine at least 6 weeks, or steroids at least 2 weeks, or immunomodulatory drugs at least 12 weeks or biologics at least 12 weeks, medical cannabis at least 2 weeks before the study; CD patients will be included if their symptoms score >4 on the Harvey-Bradshaw index (HBI) score and/or fecal calprotectin level > 150 ug/gr.
Exclusion: More than one CD luminal surgery or a small bowel length < 1.5 meter; Any proven current infection such as Clostridioides difficile infection, positive stool culture, or parasites; Subjects with chronic conditions such as cancer, organ transplant subjects, advanced kidney or liver disease, systemic inflammatory conditions other than IBD; Evidence of an abdominal abscess or entero-enteric fistula; BMI greater than 30 Kg/m2; Inability to sign informed consent and complete study protocol; Pregnancy; Presence of abscess and cysts in the liver/ kidneys or pancreas.